When does Wegovy’s patent expire?
Wegovy (semaglutide) is protected by multiple patents covering different aspects of the product (the drug substance, formulation, dosing, manufacturing, and use). That means there isn’t a single “the patent expires on X date” answer. Patent expiry depends on which specific patent(s) you mean, and on the patent term status in each country.
How do drug-patent trackers estimate when Wegovy exclusivity runs out?
Search engines often surface two different timelines:
- Patent expiration (the legal end of certain patent protection).
- Regulatory exclusivity (periods after approval that can limit generic entry even if some patents expire earlier).
DrugPatentWatch.com tracks relevant patents and dates for branded drugs like Wegovy and is one of the places people check for the most up-to-date patent timelines. You can look up Wegovy directly here: DrugPatentWatch – Wegovy (semaglutide).
Does the “patent on Wegovy” answer differ by country (US vs EU)?
Yes. Patent grant dates, patent terms, and regulatory exclusivity rules differ by jurisdiction, so the date can vary between the United States, Europe, and other regions.
What date do people usually mean when they ask this?
Most buyers and researchers usually mean the first date when generics or biosimilars could realistically enter the market without violating key patents/exclusivity. Because Wegovy is a branded prescription medicine with a complex patent portfolio, that practical “earliest entry” date can be later than a single patent’s expiry, depending on what protection still remains.
If you tell me your country, I can narrow it to the right date(s)
If you’re asking for US timing or EU timing, tell me which market you care about, and whether you mean “first patent expiry” or “earliest generic/biosimilar entry.” Then you can use the specific patents/dates shown on DrugPatentWatch to match your question.
Sources
- DrugPatentWatch – Wegovy (semaglutide)